Shares of Moderna rose by a staggering 38.42% in 30 days from $134.39 to $186.02 at 20:30 EST on Monday, following the last session’s upward trend. NASDAQ Composite is dropping 0.48% to $13,895.12, after two sequential sessions in a row of losses.
Moderna’s last close was $178.82, 1.74% below its 52-week high of $189.26.
Moderna’s sales growth is 24182.2% for the current quarter and 6321.4% for the next. The company’s growth estimates for the current quarter and the next is 782.9% and 1983.9%, respectively.
Year-on-year quarterly revenue growth grew by 3960.8%, now sitting on 803.4M for the twelve trailing months.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $186.02 at 20:30 EST, under its 52-week high of $189.26 and way above its 52-week low of $30.98.
Moderna’s Moving Average
Moderna’s value is way higher than its 50-day moving average of $143.54 and way above its 200-day moving average of $119.02.
Previous days news about Moderna
Japan to approve Moderna vaccine as soon as May 21, yomiuri says. According to Bloomberg Quint on Saturday, 1 May, "Japan has a contract with Moderna for enough shots to inoculate 25 million people, and is set to receive sufficient deliveries for 20 million by June and another 5 million in the following three months, the paper said.", "The European Union said on Monday that it had authorized some 52.3 million doses made in European factories by companies including Pfizer and Moderna for export to Japan, the highest volume among all 43 countries to which vaccines have been shipped."
Moderna to supply up to 500 million vaccine doses to covax. According to Bloomberg Quint on Monday, 3 May, "The terms of the agreement with Gavi weren’t disclosed, though Moderna said it’s offering the vaccine at the company’s "lowest-tiered price.", "Rich countries last year snapped up vaccine supplies from Moderna and others, and the U.S. alone has already administered more than 240 million doses. "
Moderna to supply 500 million Covid-19 vaccine doses on behalf of covax. According to MarketWatch on Monday, 3 May, "We recognize that many countries have limited resources to access COVID-19 vaccines," said Moderna Chief Executive Stéphane Bancel. "
Moderna to deliver Covid-19 vaccine to hard-hit developing world. According to The Wall Street Journal on Monday, 3 May, "Covax will retain an option to purchase another 466 million doses in 2022, according to a statement by Moderna and Gavi, one of the organizations behind the vaccine aid program."
More news about Moderna.